Herpes Zoster Pipeline Analysis Report 2026

Report Coverage

The Herpes Zoster Pipeline Analysis Report by Expert Market Research gives comprehensive insights into herpes zoster therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for herpes zoster. The herpes zoster report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The herpes zoster pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with herpes zoster treatment guidelines to ensure optimal care practices.

The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to herpes zoster.

Read more about this report - Request a Free Sample

Herpes Zoster Pipeline Outlook

Herpes zoster, also known as shingles, is a viral disease caused by the reactivation of the Varicella-Zoster Virus, which remains dormant in nerve tissues after a prior case of chickenpox infection. It occurs when immunity declines, leading to a painful, localized rash with fluid-filled blisters, commonly affecting older adults and immunocompromised individuals.

Herpes zoster treatment focuses on antiviral drugs such as acyclovir, valacyclovir, and famciclovir to reduce viral replication, shorten disease duration, and lower the risk of complications, along with analgesics for pain management. In July 2025, GlaxoSmithKline Plc received United States Food and Drug Administration approval for a prefilled syringe presentation of Shingrix, its Recombinant Zoster Vaccine, improving administration convenience while maintaining clinical comparability and supporting broader adult immunization efforts.

Herpes Zoster Epidemiology

The pipeline is increasingly driven by rising disease prevalence among older adults. According to Jiang Li et al., 2025, from 1992 to 2021, global incidence in adults aged 65 and older increased from 2.83 million to 6.52 million, and Disability-Adjusted Life Years rose from 90,000 to 140,000. Incidence in males increased from 1.13 million to 2.74 million, while in females it rose from 1.7 million to 3.78 million, with females showing higher age-standardized incidence rates of 899.37 compared to 802.20 in males. Southeast Asia reported the highest incidence at 1040.92, and Central Sub-Saharan Africa recorded the highest death rate at 79.94.

Herpes Zoster – Pipeline Therapeutic Assessment

Herpes Zoster Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II, with 29%, covers a major share of the total herpes zoster clinical trials, driven by active clinical trials and promising efficacy data, highlighting strong mid-stage development. Phase I and phase IV each account for 26%, reflecting ongoing early safety studies and post-marketing surveillance potential. Phase III holds 19%, supported by late-stage trials and regulatory readiness.

Herpes Zoster Pipeline Assessment Segmentation, By Drug Classes

The drug molecule categories covered under the herpes zoster pipeline analysis include small molecules, peptides, and oligonucleotides. The herpes zoster report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for herpes zoster. Vaccine-based therapies for herpes zoster are advancing to improve immunogenicity and tolerability. For instance, Amezosvatein (CRV-101), a non-mRNA, adjuvanted subunit vaccine, is under Phase 2 evaluation versus Shingrix® in adults aged 50 years and older. It has demonstrated non-inferior anti-gE antibody responses and improved tolerability, positioning it as a potential alternative in the shingles prevention landscape.

Herpes Zoster Clinical Trials – Key Players

The EMR report for the herpes zoster pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed herpes zoster therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in herpes zoster clinical trials:

• ModernaTX, Inc.
• EuBiologics Co., Ltd.
• Dynavax Technologies Corporation
• Suzhou Abogen Biosciences Co., Ltd.
• Ab&B Bio-tech Co., Ltd.
• Sinocelltech Ltd.
• GlaxoSmithKline
• Yither Biotechnology Co., Ltd.
• Curevo Inc.
• Pfizer
• BioNTech SE
• Guangzhou Patronus Biotech Co., Ltd.

Herpes Zoster – Emerging Drugs Profile

Key Questions Answered in the Herpes Zoster Pipeline Insight Report

• Which companies/institutions are leading the herpes zoster drug development?
• Which company is leading the herpes zoster pipeline development activities?
• What is the current herpes zoster commercial assessment?
• What are the opportunities and challenges present in the herpes zoster pipeline landscape?
• What is the efficacy and safety profile of herpes zoster pipeline drugs?
• Which company is conducting major trials for herpes zoster drugs?
• Which companies/institutions are involved in herpes zoster collaborations aimed at providing enhanced therapeutic alternatives for patients?
• What are the geographies covered for clinical trials in herpes zoster?

Reasons To Buy This Report

The Herpes Zoster Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for herpes zoster. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from essential insights into herpes zoster collaborations, regulatory environments, and potential growth opportunities.

Related Reports

Clinical Trials Market

Herpes Zoster Epidemiology Forecast

Herpes Simplex Epidemiology Forecast